{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:55:50Z","timestamp":1790916950501,"version":"4.1.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010888","name":"Wuhan Municipal Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome marked by inflammation, immune dysregulation, and myocardial fibrosis. Whether pyroptosis intersects with fibrotic remodeling in HFpEF remains uncertain. Two murine cardiac transcriptomic datasets were integrated after batch correction and intersected with curated pyroptosis- and myocardial fibrosis-related gene sets. Functional enrichment, univariate logistic regression, support vector machine\u2013recursive feature elimination (SVM-RFE), and least absolute shrinkage and selection operator (LASSO) regression were used for feature selection. Complete separation in the ordinary three-gene logistic fit prompted refitting with Firth bias-reduced logistic regression. Performance was assessed by apparent area under the curve (AUC), stratified bootstrap optimism correction, and repeated nested cross-validation; the panel was re-estimated in a human left-ventricular dataset for exploratory replication. Cell-type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) estimated immune-cell fractions, and expression was examined in a high-fat diet (HFD)\/N\n                    <jats:sup>\u03c9<\/jats:sup>\n                    -nitro-L-arginine methyl ester hydrochloride (L-NAME) murine model and whole blood from patients with HFpEF. Six candidates\u2014\n                    <jats:italic>Pparg<\/jats:italic>\n                    ,\n                    <jats:italic>Ace2<\/jats:italic>\n                    ,\n                    <jats:italic>Smad2<\/jats:italic>\n                    ,\n                    <jats:italic>Lcn2<\/jats:italic>\n                    ,\n                    <jats:italic>Ptpn11<\/jats:italic>\n                    , and\n                    <jats:italic>Sqstm1<\/jats:italic>\n                    \u2014were identified. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses linked them to SMAD binding, autolysosome\/amphisome activity, cellular senescence, efferocytosis, and renin-angiotensin signaling. In the 45-sample discovery cohort, the fixed\n                    <jats:italic>Pparg<\/jats:italic>\n                    -\n                    <jats:italic>Ptpn11<\/jats:italic>\n                    -\n                    <jats:italic>Ace2<\/jats:italic>\n                    Firth model had an apparent AUC of 1.0000; bootstrap correction yielded an AUC of 0.9971 (95% percentile interval, 0.9780\u20131.0000). Repeated nested cross-validation produced a mean out-of-fold AUC of 0.9286 (2.5%\u201397.5% percentile interval, 0.8726\u20130.9700), revealing additional feature-selection uncertainty. Re-estimation in the human dataset represented panel-level replication rather than validation of a locked cross-species model. No inferred immune-cell fraction differed between HFpEF and control after false-discovery-rate correction, although exploratory correlations were observed among deconvolved fractions and with\n                    <jats:italic>Ptpn11<\/jats:italic>\n                    expression. HFD\/L-NAME-treated mice developed diastolic dysfunction, reduced exercise capacity, pulmonary congestion, cardiomyocyte hypertrophy, and myocardial fibrosis despite preserved systolic function; myocardial\n                    <jats:italic>Ptpn11<\/jats:italic>\n                    ,\n                    <jats:italic>Pparg<\/jats:italic>\n                    , and\n                    <jats:italic>Ace2<\/jats:italic>\n                    transcripts and their proteins were reduced. In patients with HFpEF, whole-blood PTPN11 mRNA was lower than in controls and inversely associated with N-terminal pro-B-type natriuretic peptide and C-reactive protein; these unadjusted findings remain exploratory. The three-gene panel is hypothesis-generating rather than a stable diagnostic model; its transportability, selection stability, and clinical relevance require prospective validation.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1925067","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:39:46Z","timestamp":1790915986000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune and inflammatory features associated with pyroptosis- and myocardial fibrosis-related genes in HFpEF: a machine learning study"],"prefix":"10.3389","volume":"17","author":[{"given":"Bo","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Cardiology, Wuhan Fourth Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Wuhan Fourth Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-qiang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Wuhan Fourth Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Wuhan Fourth Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2022","journal-title":"Cardiovasc Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","volume":"403","author":"Campbell","year":"2024","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: A report of the american college of cardiology solution set oversight committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-00480-6","article-title":"Cellular and molecular pathobiology of heart failure with preserved ejection fraction","volume":"18","author":"Mishra","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2018.12.034","article-title":"Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive methods","volume":"13","author":"Obokata","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00004.2023","article-title":"Inflammatory mechanisms in heart failure with preserved ejection fraction","volume":"38","author":"Daou","year":"2023","journal-title":"Physiol (Bethesda)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-023-00946-3","article-title":"The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases","volume":"21","author":"Toldo","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.870924","article-title":"Cardiac remodeling in heart failure: role of pyroptosis and its therapeutic implications","volume":"9","author":"Chai","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01452-0","article-title":"Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial","volume":"27","author":"Lewis","year":"2021","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2024.01.015","article-title":"Utility and validity of the HFA-PEFF and H2FPEF scores in patients with symptomatic atrial fibrillation","volume":"12","author":"Ariyaratnam","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1944","article-title":"Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review","volume":"22","author":"Henkens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.102155","article-title":"HFpEF: New biomarkers and their diagnostic and prognostic value","volume":"49","author":"Shaik","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1193","article-title":"NCBI GEO: archive for functional genomics data sets-update","volume":"41","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1038\/s41467-022-31544-5","article-title":"Sex differences in heart mitochondria regulate diastolic dysfunction","volume":"13","author":"Cao","year":"2022","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1.30.1","DOI":"10.1002\/cpbi.5","article-title":"The geneCards suite: from gene data mining to disease genome sequence analyses","volume":"54","author":"Stelzer","year":"2016","journal-title":"Curr Protoc Bioinf"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6365459","article-title":"Identification of a pyroptosis-related gene signature for prediction of overall survival in lung adenocarcinoma","volume":"2021","author":"Dong","year":"2021","journal-title":"J Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10020-022-00445-0","article-title":"The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma","volume":"28","author":"Deng","year":"2022","journal-title":"Mol Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050498","article-title":"Myocardial gene expression signatures in human heart failure with preserved ejection fraction","volume":"143","author":"Hahn","year":"2021","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/srep40508","article-title":"Inference of immune cell composition on the expression profiles of mouse tissue","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky311","article-title":"GeneMANIA update 2018","volume":"46","author":"Franz","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac1067","article-title":"ChIPBase v3.0: the encyclopedia of transcriptional regulations of non-coding RNAs and protein-coding genes","volume":"51","author":"Huang","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac833","article-title":"Comparative toxicogenomics database (CTD): update 2023","volume":"51","author":"Davis","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac956","article-title":"PubChem 2023 update","volume":"51","author":"Kim","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.10117","article-title":"Structure and dynamics of liquid water with different long-range interaction truncation and temperature control methods in molecular dynamics simulations","volume":"23","author":"Mark","year":"2002","journal-title":"J Comput Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/s41467-025-56885-9","article-title":"FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2894","article-title":"Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension","volume":"25","author":"Anker","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa324","article-title":"Cardiac fibrosis","volume":"117","author":"Frangogiannis","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.624112","article-title":"PPARgamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action","volume":"12","author":"Hernandez-Quiles","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa217","article-title":"Metabolic inflammation in heart failure with preserved ejection fraction","volume":"117","author":"Schiattarella","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.65802","article-title":"CXCR4-dependent macrophage-to-fibroblast signaling contributes to cardiac diastolic dysfunction in heart failure with preserved ejection fraction","volume":"18","author":"Zhang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000397","article-title":"Activation of peroxisome proliferator-activated receptor \u03b3 Prevents development of heart failure with preserved ejection fraction; inhibition of wnt-\u03b2-catenin signaling as a possible mechanism","volume":"68","author":"Kamimura","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318988","article-title":"SIRT6 mitigates heart failure with preserved ejection fraction in diabetes","volume":"131","author":"Wu","year":"2022","journal-title":"Circ Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1042\/CS20200478","article-title":"ACE2 in the renin-angiotensin system","volume":"134","author":"Verano-Braga","year":"2020","journal-title":"Clin Sci (Lond)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1340726","article-title":"Tyrosine phosphatase PTPN11\/SHP2 in solid tumors - bull\u2019s eye for targeted therapy","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe2587","article-title":"SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations","volume":"13","author":"Paccoud","year":"2021","journal-title":"Sci Transl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.123.319663","article-title":"Protein tyrosine phosphatase SHP2 in macrophages acts as an antiatherosclerotic regulator in mice","volume":"44","author":"Wu","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.011792","article-title":"Proteomics identify clinical phenotypes and predict functional outcomes in heart failure with preserved ejection fraction: insights from VITALITY-HFpEF","volume":"17","author":"deFilippi","year":"2024","journal-title":"Circ Heart Fail"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/JCI171874","article-title":"Impaired T cell IRE1\u03b1\/XBP1 signaling directs inflammation in experimental heart failure with preserved ejection fraction","volume":"133","author":"Smolgovsky","year":"2023","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.122.320257","article-title":"Heart failure with preserved ejection fraction: heterogeneous syndrome, diverse preclinical models","volume":"130","author":"Roh","year":"2022","journal-title":"Circ Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12933-025-02612-z","article-title":"Challenges in the diagnosis of heart failure with preserved ejection fraction in individuals with obesity","volume":"24","author":"van Dalen","year":"2025","journal-title":"Cardiovasc Diabetol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1925067\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:39:59Z","timestamp":1790915999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1925067\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2026.1925067"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1925067","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1925067"}}